Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OrphoMed, Inc.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Appointments: Oculis, PellePharm, Syntimmune, Sterna Biologicals, Proclara Biosciences, Denovo Biopharma and OrphoMed
The latest biopharma industry appointments include new CEOs at Oculis, PellePharm, Syntimmune and Sterna Biologicals and a new CFO at Oculis, as well as new CMOs at Proclara Biosciences, Denovo Biopharma and OrphoMed.
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.